MGX
Metagenomi, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.86%Year over year
Reported trailing growth
- Revenue
- -59.8%
- EBITDA
- -7.5%
- EBIT
- -9.5%
- EPS
- -5.5%
- Free cash flow
- +13.3%
- Operating cash flow
- +11.9%
Forward estimates
Based on analyst estimates
- Revenue
- -22.9%
- EBITDA
- +14.4%
- EPS
- +13.9%
Three-year CAGR
- Revenue
- +13.6%
- EBITDA
- -5.7%
- EBIT
- -8.0%
- Net income
- -12.6%
- EPS
- -12.9%
- Free cash flow
- +20.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026